Announcement of UPDATES to New Medicine-Oncology KnowledgeBase Data Base for September 2014
October 29, 2014 by 2012pharmaceutical
Announcement of UPDATES to New Medicine-Oncology KnowledgeBase Data Base for September 2014
Curator: Katie Siafaca
Latest Updates
September 2014 New Drug Updates and Additions
| Designation |
Brand Name |
Generic Name |
| OncoVEX GM-CSF, OncoVEXGMCSF, OncoVEXGM-CSF, Tvec, t-vec |
|
Talimogene laherparepvec |
| IL-17E |
|
|
| BIBF 1120 |
Vargatef |
Nintedanib |
| CV9202 |
|
|
| CV9104 |
|
|
| EPZ005687, EPZ-6438, E7438 |
|
|
| EPZ-5676, EPZ004777 |
|
|
| RG3638, anti-c-Met, PRO143966, RO5490258 |
MetMab |
Onartuzumab |
| G-202 |
|
Mipsagargin |
| AB0024, GS-6624 |
|
Simtuzumab |
| GS-5745 |
|
|
| PEGPH20 |
|
|
| L-DOS47 |
|
|
| IPI-145 |
|
Duvelisib |
| KTN3379 |
|
|
| 5B1 |
|
|
| MEDI4736 |
|
|
| L-BLP25, BLP-25 (formerly BP1-7-KLH), EMD531444, emepepimut-S |
Formerly Stimuvax |
Tecemotide |
| MSB0010718C |
|
|
| MM-121, MM121, SAR256212 |
|
|
| PEP02, MM-398, nal-IRI |
|
|
| CRA-024781, CG-781, PCI-24781, S-78454 |
|
Abexinostat |
| RX-3117 |
|
|
| TG4010, MVA-MUC-1-IL-2, MVA-MUC1-IL-2 |
|
|
|
September 2014 Marketed Drug Updates and Additions
| Brand Name |
Generic Name |
Other Designation |
| Pixuvri |
Pixantrone dimaleate |
BBR 2778 |
| Cyramza |
Ramucirumab |
IMC-1121b, IMC 1121B, LY3009806 |
| Perjeta (formerly Omnitarg) |
Pertuzumab |
RG1273, R1273, 2C4, rhuMAb-2C4 |
| Zydelig |
Idelalisib |
CAL-101, GS-1101 |
| Keytruda |
Pembrolizumab (formerly lambrolizumab) |
MK-3475 |
| Lymphoseek |
Technetium Tc 99m tilmanocept |
|
| Zykadia |
Ceritinib |
LDK378 |
| Afinitor |
Everolimus |
RAD001, RAD001C |
| Zelboraf |
Vemurafenib |
PLX4032, PLX4720, RG7204, RO5185426 |
|
September 2014 Company Updates and Additions
- AADi
- Abcodia
- Accelovance
- Adimab
- Affymax
- Akinion Pharmaceuticals
- Aprea
- Aptose Biosciences
- BeiGene
- Bioceros
- Biogen Idec
- Blueprint Medicines
- BTG
- Can-Fite BioPharma
- Caris Life Sciences
- Celgene
- Cellerant Therapeutics
- Champions Oncology
- CureVac
- DanDrit Biotech
- Epizyme
- Eutropics Pharmaceuticals
- F2G
- Genetic Technologies
- Ignyta
- ImaginAb
|
- Johnson & Johnson (J&J)
- Karolinska Development
- Kolltan Pharmaceuticals
- Lpath
- Merus
- Novartis
- OncoCyte
- Oncology Analytics (OA)
- OncoNOx
- Oncothyreon
- Personal Genome Diagnostics (PGDx)
- ProNAi Therapeutics
- Propanc Health Group
- Protagonist Therapeutics
- Regeneron Pharmaceuticals
- Relmada Therapeutics
- Rosetta Genomics
- Scholar Rock
- Sentinel Oncology
- Sevion Therapeutics
- SutroVax
- to-BBB Technologies (to-BBB)
- Transgene
- Veracyte
- Zenith Epigenetics
|
September 2014 Targets in Oncology Updates and Additions
- Fibroblast growth factor receptor 4 (FGFr4)
- KIT
- MUC16
- V-raf murine sarcoma viral oncogene homolog B1 (BRAF)
|
SOURCE
http://www.nmok.net/oksite/updates.html
From: info <info@newmedinc.com>
Reply-To: <info@newmedinc.com>
Date: Wed, 29 Oct 2014 13:41:44 -0700
To: “Aviva Lev-Ari, PhD, RN” <avivalev-ari@alum.berkeley.edu>
Subject: DB coverage
Like this:
Like Loading...
Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, FDA, Pharmaceutical Analytics, Pharmaceutical Discovery, Pharmaceutical Drug Discovery, Pharmaceutical Industry Competitive Intelligence, Pharmaceutical R&D Investment, Pharmacodynamics and Pharmacokinetics, Pharmacogenomics, Pharmacologic toxicities, Regulated Clinical Trials: Design, Methods, Components and IRB related issues | Leave a Comment
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aptubman
Arav Gandhi
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply